Showing results (31-40 of 296) with videos related to
Sort By:
Pageof 30
Clinical Advances in Hematology & Oncology : H&O|March 13, 2012
The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancerAndrew J Armstrong, Anna C Ferrari, David I QuinnClinics in Geriatric Medicine|November 29, 2015
Management of Prostate Cancer in the ElderlyKae Jack Tay, Judd W Moul, Andrew J ArmstrongClinical Medicine Insights. Oncology|November 16, 2011
Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?Rhonda L Bitting, Andrew J Armstrong, Daniel J GeorgeBJU International|April 20, 2007
Anti-angiogenic therapy in renal cell cancerRamaprasad Srinivasan, Andrew J Armstrong, William Dahut, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomesRahul Aggarwal, Tian Zhang, Eric J Small, et al.BMJ Case Reports|January 30, 2023
Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancerAmanda Broderick, Matthew K Labriola, Neal Shore, et al.Expert Opinion on Pharmacotherapy|December 24, 2014
Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancerTian Zhang, Jason Zhu, Daniel J George, et al.Prostate Cancer and Prostatic Diseases|December 22, 2017
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivationMegan McNamara, Christopher Sweeney, Emmanuel S Antonarakis, et al.Precision Clinical Medicine|January 29, 2019
The promise of immunotherapy in genitourinary malignanciesTian Zhang, Andrew J Armstrong, Daniel J George, et al.The Urologic Clinics of North America|October 29, 2022
Molecular Mechanisms of Castrate-Resistant Prostate CancerSrinath Kotamarti, Andrew J Armstrong, Thomas J Polascik, et al.Pageof 30